Ipsen S.A. publishes its 2024 consolidated financial statements

February 21, 2025 09:42 ET | Source: Ipsen Pharma Ipsen Pharma

Ipsen S.A. - 2024 Consolidated Financial Statements

Attachment

Ipsen_Consolidated financial statements 2024_EN

Attachments

Ipsen_Consolidated financial statements 2024_EN

Ipsen_Consolidated financial statements 2024_EN...

Recommended Reading

February 27, 2026 06:20 ET | Source: Ipsen Pharma

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma,...
Read More

$Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma$
February 19, 2026 04:26 ET | Source: Ipsen Pharma

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment Ipsen_Consolidated financial statements 2025_GB ...
Read More